IL271100A - A method for reducing or preventing cardiovascular events in patients with type ii diabetes mellitus - Google Patents

A method for reducing or preventing cardiovascular events in patients with type ii diabetes mellitus

Info

Publication number
IL271100A
IL271100A IL271100A IL27110019A IL271100A IL 271100 A IL271100 A IL 271100A IL 271100 A IL271100 A IL 271100A IL 27110019 A IL27110019 A IL 27110019A IL 271100 A IL271100 A IL 271100A
Authority
IL
Israel
Prior art keywords
patients
reducing
type
diabetes mellitus
cardiovascular events
Prior art date
Application number
IL271100A
Other languages
English (en)
Hebrew (he)
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of IL271100A publication Critical patent/IL271100A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/38Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL271100A 2017-06-12 2019-12-02 A method for reducing or preventing cardiovascular events in patients with type ii diabetes mellitus IL271100A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762518547P 2017-06-12 2017-06-12
PCT/IB2018/054208 WO2018229630A1 (en) 2017-06-12 2018-06-11 Method for reducing or preventing cardiovascular events in patients with type ii diabetes mellitus

Publications (1)

Publication Number Publication Date
IL271100A true IL271100A (en) 2020-01-30

Family

ID=62916717

Family Applications (1)

Application Number Title Priority Date Filing Date
IL271100A IL271100A (en) 2017-06-12 2019-12-02 A method for reducing or preventing cardiovascular events in patients with type ii diabetes mellitus

Country Status (15)

Country Link
US (2) US20180353470A1 (enExample)
EP (1) EP3638250A1 (enExample)
JP (2) JP2020523408A (enExample)
KR (1) KR20200014406A (enExample)
CN (1) CN110740735A (enExample)
AU (1) AU2018283781B2 (enExample)
BR (1) BR112019026120A2 (enExample)
CA (1) CA3066874A1 (enExample)
CO (1) CO2019013940A2 (enExample)
EA (1) EA202090028A1 (enExample)
IL (1) IL271100A (enExample)
MX (1) MX2019014988A (enExample)
TW (1) TWI835735B (enExample)
UA (1) UA127987C2 (enExample)
WO (1) WO2018229630A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI827184B (zh) * 2021-08-03 2023-12-21 國立政治大學 第2型糖尿病併發症的風險評估系統與方法
CN117085009B (zh) * 2023-10-20 2024-01-30 首都医科大学附属北京天坛医院 卡格列净对急性缺血性卒中的治疗作用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2514756B1 (en) 2003-08-01 2014-12-17 Mitsubishi Tanabe Pharma Corporation Novel compounds having inhibitory activity against sodium-dependant glucose transporter
UY30730A1 (es) 2006-12-04 2008-07-03 Mitsubishi Tanabe Pharma Corp Forma cristalina del hemihidrato de 1-(b (beta)-d-glucopiranosil) -4-metil-3-[5-(4-fluorofenil) -2-tienilmetil]benceno
DK2385374T4 (en) * 2010-05-05 2018-04-30 Zora Biosciences Oy LIPIDOMICS BIOMARKERS FOR ATHEROSCLEROSIS AND CARDIOVASCULAR DISEASE
CN102985075A (zh) * 2010-05-11 2013-03-20 田边三菱制药株式会社 含卡纳格列净的片剂
US20160000816A1 (en) * 2013-04-05 2016-01-07 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
CA2812016A1 (en) * 2013-04-05 2014-10-05 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
CA2938406A1 (en) * 2014-01-31 2015-08-06 Janssen Pharmaceutica Nv Methods for the treatment and prevention of renal disorders and fatty liver disorders
US20170071970A1 (en) * 2015-09-15 2017-03-16 Janssen Pharmaceutica Nv Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders

Also Published As

Publication number Publication date
KR20200014406A (ko) 2020-02-10
EP3638250A1 (en) 2020-04-22
TWI835735B (zh) 2024-03-21
US20210000792A1 (en) 2021-01-07
US20180353470A1 (en) 2018-12-13
CO2019013940A2 (es) 2020-01-17
JP2020523408A (ja) 2020-08-06
AU2018283781A1 (en) 2019-12-19
AU2018283781B2 (en) 2023-09-28
WO2018229630A1 (en) 2018-12-20
CA3066874A1 (en) 2018-12-20
CN110740735A (zh) 2020-01-31
JP2023113644A (ja) 2023-08-16
UA127987C2 (uk) 2024-03-06
TW201904584A (zh) 2019-02-01
EA202090028A1 (ru) 2020-04-03
BR112019026120A2 (pt) 2020-07-07
MX2019014988A (es) 2020-08-06

Similar Documents

Publication Publication Date Title
ZA202007993B (en) Methods of reducing the risk of cardiovascular events in a subject
TWI563057B (en) Adhesive film, adhesive composition, and display apparatus including the same
LT3283551T (lt) Aktyvintas lignino mišinys, jo gamybos ir naudojimo būdas
SG11201709426XA (en) Resin composition, film produced by using the resincomposition, and multilayer structure
EP3113627A4 (en) Low calorie sugar substitute composition and methods for making the same
EP3175619A4 (en) Golden frame selection in video coding
IL254496A0 (en) Treatment of type 2 diabetes patients
IL259183B (en) Food supplement and preparation for the treatment of metabolic syndrome
EP3013219A4 (en) Low glucose treatment for people with diabetes
PL3365507T3 (pl) Struktura wielowarstwowa zawierająca vip i sposób jej wytwarzania
IL273016A (en) Genotype stratification in the treatment and prevention of diabetes
SG11201803938RA (en) Polymetalloxane, method for producing same, composition thereof, cured film and method for producing same, and members and electronic components provided with same
PL3027055T3 (pl) Pochodząca z ziemniaków kompozycja wzmacniacza smaku i sposób jej wytwarzania
IL271100A (en) A method for reducing or preventing cardiovascular events in patients with type ii diabetes mellitus
EP3053449A4 (en) Fat composition for non-tempered chocolate and fat composition for tempered chocolate
CA3269825A1 (en) Methods of reducing the risk of cardiovascular events in a subject
ZA201509103B (en) A composition, process and a kit for sugar processing
GB201807648D0 (en) A frame for use in connection with a structure
EP3013958A4 (en) Glucan-encapsulated sirna for treating type 2 diabetes mellitus
GB201507914D0 (en) A picture frame, a picture frame kit and a method for making a picture frame
PT3007683T (pt) Composição para administração oral de magnésio, em associação com uma composição para o tratamento de diabetes tipo 2 e suas complicações
GB201702652D0 (en) Delta-theraphotoxin-Ac1 for use in treating diabetes
WO2018100581A9 (en) Compound for diabetes mellitus type 2 and insulin resistance
IL255665A0 (en) A method for delaying insulin-dependent diabetes
EP3071195A4 (en) Regimen and method for treatment of type 2 diabetes